Jamie M O'sullivan

List of Publications by Year
in descending order

43 papers	1,992 citations	236925 25 h-index	276875 41 g-index
43 all docs	43 docs citations	43 times ranked	3227 citing authors

#	Article	IF	Citations
1	Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance. Haematologica, 2022, 107, 668-679.	3.5	8
2	Persistent endotheliopathy in the pathogenesis of long COVID syndrome â€•Reply to comment from von Meijenfeldt et al.. Journal of Thrombosis and Haemostasis, 2022, 20, 270-271.	3.8	5
3	Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 214-228.	2.1	1
4	Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. Haematologica, 2022, 107, 1950-1954.	3.5	3
5	The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies. Journal of Thrombosis and Haemostasis, 2022, 20, 1766-1777.	3.8	10
6	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. Journal of Thrombosis and Haemostasis, 2022, 20, 2350-2365.	3.8	18
7	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. Journal of Thrombosis and Haemostasis, 2021, 19, 701-710.	3.8	7
8	Advances in the Management of Cancer-Associated Thrombosis. Seminars in Thrombosis and Hemostasis, 2021, 47, 139-149.	2.7	16
9	Personalized Approaches to the Treatment of Hemostatic Disorders. Seminars in Thrombosis and Hemostasis, 2021, 47, 117-119.	2.7	1
10	Prolonged elevation of Dâ€dimer levels in convalescent COVIDâ€19 patients is independent of the acute phase response. Journal of Thrombosis and Haemostasis, 2021, 19, 1064-1070.	3.8	142
11	The role of von Willebrand factor in breast cancer metastasis. Translational Oncology, 2021, 14, 101033.	3.7	18
12	The Biological Significance of von Willebrand Factor O-Linked Glycosylation. Seminars in Thrombosis and Hemostasis, 2021, 47, 855-861.	2.7	10
13	ADAMTS13 regulation of VWF multimer distribution in severe COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	3.8	58
14	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
15	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Journal of Thrombosis and Haemostasis, 2021, 19, 2546-2553.	3.8	208
16	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVIDâ€19): evidence of acute and sustained endothelial cell activation. British Journal of Haematology, 2021, 192, 714-719.	2.5	92
17	The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood, 2020, 136, 2864-2874.	1.4	75
18	Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor. Scientific Reports, 2020, 10, 18366.	3.3	3

#	Article	IF	Citations
19	More on â€˜Association between ABO blood groups and risk of SARSâ€CoVâ€2 pneumoniaâ€™. British Journal of Haematology, 2020, 190, 27-28.	2.5	35
20	More on COVIDâ€19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1060-1061.	2.5	73
21	Investigating the clearance of VWF Aâ€domains using siteâ€directed PEGylation and novel Nâ€linked glycosylation. Journal of Thrombosis and Haemostasis, 2020, 18, 1278-1290.	3.8	8
22	Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematology,the, 2020, 7, e553-e555.	4.6	122
23	Von Willebrand factor and cancer; metastasis and coagulopathies. Journal of Thrombosis and Haemostasis, 2020, 18, 2444-2456.	3.8	54
24	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	2.5	307
25	Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. EMBO Molecular Medicine, 2020, 12, e12143.	6.9	3
26	von Willebrand factor promotes wound healing. Blood, 2019, 133, 2553-2555.	1.4	2
27	von Willebrand factor sialylationâ€”A critical regulator of biological function. Journal of Thrombosis and Haemostasis, 2019, 17, 1018-1029.	3.8	30
28	Advances in understanding the molecular mechanisms of venous thrombosis. British Journal of Haematology, 2019, 186, 13-23.	2.5	31
29	Advances in understanding the molecular mechanisms that maintain normal haemostasis. British Journal of Haematology, 2019, 186, 24-36.	2.5	46
30	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	1.4	32
31	Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood, 2019, 133, 1371-1377.	1.4	36
32	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood, 2018, 131, 911-916.	1.4	54
33	Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Seminars in Thrombosis and Hemostasis, 2018, 44, 159-166.	2.7	34
34	von Willebrand factor clearance â€“ biological mechanisms and clinical significance. British Journal of Haematology, 2018, 183, 185-195.	2.5	51
35	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	5.2	79
36	The Low Von Willebrand Factor in Ireland Cohort Study - Defining Optimal Management for Procedures in Patients with Low VWF (30-50 IU/dL). Blood, 2018, 132, 1178-1178.	1.4	0

#	Article	IF	Citations
37	Site-Directed Pegylation at Specific Sites Significantly Prolongs the Half-Life of A1A2A3-VWF By Markedly Attenuating LRP1-Mediated Clearance. Blood, 2018, 132, 1165-1165.	1.4	0
38	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1â€“A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 845-855.	2.4	29
39	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	1.4	98
40	A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. Blood, 2016, 127, 1192-1201.	1.4	41
41	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. Blood, 2016, 128, 1959-1968.	1.4	31
42	Emerging roles for hemostatic dysfunction in malaria pathogenesis. Blood, 2016, 127, 2281-2288.	1.4	54
43	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood, 2013, 122, 4107-4110.	1.4	65